Effectiveness and Safety of Baricitinib in Patients With Moderate-to-Severe Refractory Alopecia Areata in Real World: An Open-Label, Single-Center Study

December 2023 in “ Journal of Cosmetic Dermatology ”

Lingbo Bi, Chaofan Wang, Yimei Du, Tong Su, Zhao Min, Xuewen Lin, Weifei Fan, Weiyuan Sun

baricitinib JAK inhibitor alopecia areata Severity of Alopecia Tool SALT score platelet elevation elevated transaminase dizziness tonsillitis acne

TLDR Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

The study involved 32 patients with moderate to severe alopecia areata (AA) who were unresponsive to traditional treatments. These patients were treated with baricitinib, a JAK inhibitor, for 24 weeks. The results showed a significant decrease in the Severity of Alopecia Tool (SALT) score from baseline at week 12 and 24, indicating improved hair growth. By the end of the study, 68.75% of patients reported over 80% hair covering of the scalp. Side effects were mild and included transient platelet elevation, elevated transaminase, dizziness, tonsillitis, and acne. The study concluded that baricitinib is effective and safe for treating patients with refractory AA at moderate to severe levels.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Cited in this study

13 / 13 results

research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata

1 citations , September 2023 in “JAMA Dermatology”

Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.

research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials

20 citations , March 2023 in “American Journal of Clinical Dermatology”

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis

10 citations , January 2023 in “Acta dermato-venereologica”

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

$Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population$

research Real-World Experience and Long-Term Evaluation of Tofacitinib in Refractory Alopecia Areata: A Prospective, Open-Label, Single-Center Study in Asian Arab Population

2 citations , December 2022 in “Dermatologic Therapy”

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.

$Efficacy and Safety of Baricitinib in Patients With Refractory Alopecia Areata$

research Efficacy and Safety of Baricitinib in Patients With Refractory Alopecia Areata

4 citations , October 2022 in “Dermatologic Therapy”

Baricitinib helped some patients with tough-to-treat hair loss regrow hair, but more research is needed on its safety.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , May 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Alopecia Areata: A Multifactorial Autoimmune Condition

148 citations , March 2019 in “Journal of autoimmunity”

Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.

research JAK-Inhibitors in Dermatology: Current Evidence and Future Applications

45 citations , December 2018 in “Journal of dermatological treatment”

JAK-inhibitors are effective for treating psoriasis and show promise for other skin diseases.

research Objective Outcome Measures: Collecting Meaningful Data on Alopecia Areata

39 citations , September 2018 in “Journal of The American Academy of Dermatology”

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

research Alopecia Areata: Treatment Options and Efficacy

182 citations , January 2018 in “Journal of the American Academy of Dermatology”

Some treatments can help with a hair loss condition called alopecia areata, but none ensure lasting results; choices depend on the person, with JAK inhibitors showing promise for severe cases.

1 / 1 results

research Serum Zinc Concentration in Patients With Alopecia Areata

October 2023 in “Acta dermato-venereologica (Print)”

People with severe hair loss have lower zinc levels in their blood.